
Opinion|Videos|March 6, 2025
Updates From the RATIONALE-306 Trial
The panelists discuss how the RATIONALE-306 trial demonstrated efficacy outcomes through its design, measuring both progression-free survival and overall survival as key end points.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
4
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
5



















